The HER2 gene is an important prognostic and therapeutic marker in newly diagnosed breast cancer. Currently, HER2 status is most frequently determined by immunohistochemical detection of HER2 protein expression on the cellular membrane surface or by fluorescence in situ hybridization analysis of HER2 gene copy number in fixed tissue using locus-specific probes for the HER2 gene and chromosome 17 centromere. However, these methods are problematic because of issues with intra-and inter-laboratory reproducibility and preanalytic variables, such as fixation time. In addition, the commonly used HER2/chromosome 17 ratio presumes that chromosome 17 polysomy is present when the centromere is amplified, even though analysis of the rest of the chromosome is not included in the assay. In this study, 97 frozen samples of invasive lobular and invasive ductal carcinoma, with known immunohistochemistry and fluorescence in situ hybridization results for HER2, were analyzed by comparative genomic hybridization to a commercially available bacterial artificial chromosome whole-genome array containing 99 probes targeted to chromosome 17 and the HER2/TOP2 amplicon. Results were 97% concordant for HER2 status, meeting the College of American Pathologists/ American Society of Clinical Oncology's validation requirements for HER2 testing. Surprisingly, not a single case of complete polysomy 17 was detected even though multiple breast cancer cases showed clear polysomies of other chromosomes. We conclude that array comparative genomic hybridization is an accurate and objective DNA-based alternative for clinical evaluation of HER2 gene copy number, and that polysomy 17 is a rare event in breast cancer.
The human HER2 gene is present on chromosome 17q11 and encodes a membrane receptor tyrosine kinase protein. It is overexpressed in 15-30% of breast cancer cases and overexpression is most commonly because of gene amplification. 1 Standard testing methods include analysis of gene copy number by fluorescence in situ hybridization (FISH), as well as immunohistochemical staining of the HER2 membrane protein. HER2 testing in breast cancer is important for prognosis, and accuracy of testing is crucial for the correct identification of patients who will benefit from trastuzumab (Herceptin) therapy, a humanized monoclonal antibody, and lapatinib (Tykerb), a small molecule tyrosine kinase inhibitor. These therapies are generally only effective in patients with HER2-amplified tumors, and may have significant toxicities and costs. Yet, it is estimated by the American Society of Clinical Oncology (ASCO)/ College of American Pathologists (CAP) that approximately 20% of current HER2 testing may be inaccurate owing to multiple preanalytic, analytic, and postanalytic variables. 2 The unreliability of current HER2 testing methods is illustrated by recent studies showing that some patients who tested negative for HER2 amplification by immunohistochemistry and FISH may still benefit from trastuzumab. 3, 4 It has been proposed that this discrepancy is not because of misunderstanding the mechanism of action of the drug, but rather because of the inaccuracy of current testing methods. 5 Currently available FDA-approved FISH assays for the detection of HER2 gene amplification include an assay with a single probe for the HER2 gene and other assays with dual probes, one for the HER2 gene and another for the centromere of chromosome 17 (probe CEP 17, D17Z1). At this time, assays with dual probes are more widely used.
Recent papers stress that an important source of HER2 testing inaccuracy may be owing to 'polysomy 17', referring to breast cancer cases in which there are presumed to be multiple copies of chromosome 17 . In clinical trials, polysomy is a defined condition when the number of a particular chromosome is greater than diploid, meaning that there may be three or more copies of the chromosome, rather than the expected two copies. Polysomy 17 is considered to be present in breast cancer cases that show Z3 signals in FISH assays with a probe targeted to the centromere of chromosome 17. Chromosomal aneusomy based on this finding has been reported in a significant number of breast carcinomas, and polysomy 17, in addition to HER2 gene amplification, has been associated with HER2 protein overexpression. [6] [7] [8] [9] This has led to the assumption that increased numbers of the chromosome 17 centromere are representative of the presence of additional copies of chromosome 17 in the tumor genome. Correction for chromosome 17 polysomy using the HER2 to chromosome 17 ratio is, therefore, considered to be critical for distinguishing true HER2 gene amplification from increased chromosome 17 copy numbers. 10, 11 However, it may not be prudent to determine chromosome 17 copy number based on the amplification of a single probe, because amplification of the chromosome 17 centromere probe may actually mask HER2 gene amplification. 12, 13 Although by using multiple chromosome 17 probes for HER2, FISH undoubtedly provides a better representation of the true copy number of the chromosome, this approach is impractical for a clinical assay. Array comparative genomic hybridization (array CGH) is available as an alternative to current, commonly used methods that can provide high-throughput, high-resolution, genome-wide copy number analysis in a single test. 14, 15 Array CGH was initially developed as a research tool for evaluation of gene dosage variations in many disorders (including breast cancer), [16] [17] [18] [19] and arraybased testing is now the standard of care for detection of congenital genomic abnormalities. 20 Array CGH has broad applications for cancer analysis and has recently entered into clinical use for genome scanning in chronic lymphocytic leukemias. [21] [22] [23] [24] In this study, we used bacterial artificial chromosome (BAC)-based array CGH to evaluate 97 frozen samples of invasive lobular and invasive ductal breast carcinoma. A commercially available microarray with whole-genome coverage was used for this analysis that included probes specifically targeted to the HER2/TOP2 amplicon as well as additional probes covering the length of chromosome 17. The breast cancers included in this study had known HER2 results obtained using clinically validated immunohistochemistry and FISH assays.
Concordance of HER2 status and frequency of complete gain of chromosome 17 was calculated. A subset of the samples was also evaluated by array CGH using an earlier described fresh tissue preservation protocol for procurement of surgical samples for the clinical laboratory. Microarray analysis results from the processed samples were compared with the results obtained from the nonprocessed samples.
Materials and methods
Fresh frozen tissues from 97 breast cancer cases were analyzed, including 86 invasive ductal carcinomas, 10 invasive lobular carcinomas, and one case with mixed ductal-lobular features. Optimum cutting temperature (OCT) compound was used to make frozen tissue blocks. H and E stained sections cut from the OCT blocks were reviewed, and a 4 mm punch was used to select 25-50 mg regions of tumor tissue for subsequent DNA extraction. The tissue samples were placed into 1.5 ml microfuge tubes and stored at À801C until DNA isolation. A minimum of 2 mg DNA was isolated from each case using a Promega Maxwell 16 automated nucleic acid isolation instrument (Madison, WI, USA). Verification of the presence of high-molecular-weight DNA was accomplished by agarose gel electrophoresis. Array CGH analysis of the tumor genomes was carried out in the Combimatrix Molecular Diagnostics Laboratory (Irvine, CA, USA) using a BAC array comprised of up to 1526 clones for whole-genome coverage, which also included three overlapping clones for the HER2 locus (RP11-62N23, RP11-94L15, RP11-387H17), and 96 clones for coverage of chromosome 17 and the HER2/TOP2A amplicon (genes PPARBP, PPP1R1B, STARD3, TCAP, PNMT, PERLD1, GRB7, GSDML, PSMD3, CASC3, RARA, TOP2A, and SMARCE1). 24, 25 Tumor genomic DNA (test DNA) and male reference DNA (as an internal control) were differentially fluorescence-labeled with Alexa Fluor 555 and Alexa Fluor 647 (Invitogren, Carlsbad, CA, USA) in dye-swap reactions and hybridized to the BAC arrays. The hybridized microarray slides were scanned and quantified with GenePix 4000B scanner and GenePix Pro Software (Axon Ins. Inc., Union City, CA, USA). Normalized Alexa Fluor 555 to Alexa Fluor 647 intensity ratios were computed for each of the two reactions and plotted together for each chromosome. A ratio plot was assigned such that gains in DNA copy number at a particular locus are observed as the simultaneous deviation of the ratio plots from a modal value of 1.0, with blue ratio plots representing gain of genetic material, showing a positive deviation (to the right), and red ratio plots representing loss of genetic material, showing a negative deviation at the same locus (to the left). Array CGH results for HER2 copy number were scored based on the average of the forward reaction fluorescence intensity ratios for the three replicates of the BAC clone containing the HER2 gene (clone RP11-94L15) as follows: o0.8, loss; 0.8 to o1.5, normal; 1.5-3.5, gain; 43.5, amplified ( Table 1 ).
All cancers were tested for HER2 using an algorithm recommended by the ASCO/CAP guidelines. 2 The tumors were initially tested by immunohistochemistry using the monoclonal antibody, TAB250 (Zymed Laboratories, South San Francisco, CA, USA), followed by FISH in cases that were equivocal by immunohistochemistry (scored as 2 þ ). FISH analysis was carried out using the Vysis PathVysion HER-2 DNA Probe Kit (Abbott Molecular, Abbott Park, IL, USA), which includes a chromosome 17 centromere probe and a HER2 probe. Array CGH results were correlated to the FISH results and scored as follows: loss or normal ¼ negative; gain or amplified ¼ positive ( Table 1 ). Cases that showed discordant array CGH and FISH results were retested by FISH. In all, a total of 29 cases were tested by FISH.
A second subset of cases, HER2 positive (n ¼ 5) and HER2 negative (n ¼ 5), were thawed and stored for at least 48 h in RNAlater (Applied Biosystems, Foster City, CA, USA) according to an earlier described multidisciplinary tumor bank procurement protocol for tissue and nucleic acid preservation of resection specimens. 25, 26 Sections were cut for H and E staining followed by tumor-targeted DNA extraction for array CGH analysis. Results from the RNAlater processed samples were compared with the results obtained from frozen non-processed samples.
Results
Array CGH results were 97% concordant with immunohistochemistry/FISH results for HER2 status, with a sensitivity and specificity of 91 and 99%, respectively. Positive predictive value was 95% and negative predictive value 97%. Of the 76 cases that were scored as HER2 negative by immunohistochemistry/FISH, 67 showed two copies of the HER2 gene (HER2 negative) by array CGH, seven showed loss of one copy of the HER2 gene (HER2 negative), and one tumor sample showed a gain in HER2 copy number (HER2 positive). A total of 21 cases were positive by immunohistochemistry/FISH, with 16 of these cases showing amplification by array CGH, three cases showing gains, and two cases showing normal results (Table 2 ). Discordant samples consisted of one immunohistochemistry/FISH-negative sample that showed gain of HER2 by array CGH, and two immunohistochemistry/FISH-positive samples that were negative by array CGH. Further review of the 'false positive' case showed the histology to be a mixed in situ and invasive ductal carcinoma, with the in situ component showing HER2 positivity by immunohistochemistry, but negative HER2 in the invasive component. Of the two 'false negatives', one case was positive by immunohistochemistry (3 þ ); FISH testing showed an equivocal result with a ratio of 2.1. The second case was a borderline immunohistochemistry (2 þ )/FISH low positive, ratio 2.9 (Table 3 ). Further analysis of the array CGH results in the second case showed amplification of a nearby region at17q21, but the HER2 locus at 17q12 was normal.
By FISH, 2 of our 97 cases showed a HER2 to chromosome 17 centromere ratio of 43 and would have been classified as polysomy 17 by FISH. Of these, one was HER2 amplified and the other was not. Multiple abnormalities were identified on chromosome 17 by array CGH, including losses and gains of genetic material in both the p and q arms, as well as six cases with gains of the centromeric region and 10 cases with loss (Figure 1a-c) . Three of six cases with centromeric gains also showed HER2 amplification (Figure 1d ). Although multiple chromosomes in our study exhibited recurrent whole chromosome polysomy by array CGH, no cases showed complete polysomy of chromosome 17 (Table 4 and Figure 2 ).
In the subset of cases processed in RNAlater, tissue architecture was preserved for tumor-targeted DNA extraction, and all 10 samples yielded high-quality high-molecular-weight DNA for subsequent array CGH analysis. HER2 copy number was concordant with previously determined HER2 copy number results from the frozen tissue, and similar whole-genome array CGH results were obtained (Figure 3 ).
Discussion
Analysis of 97 breast carcinoma samples by array CGH revealed 97% concordance with previously a Chromosome polysomy is defined as a gain of all of the BAC clones covering a chromosome. However, some of these polysomy cases have isolated single clones that do not show gain. Isolated single clone changes generally represent polymorphic regions of the genome, so chromosomes in our study with gains of all but a single clone are described as showing polysomy, and considered to represent complete single copy gain of DNA content.
represent one case in which the HER2 FISH probe may have picked up amplification of a nearby genomic region, and another case showing HER2 protein overexpression without gene amplification (Table 3) . Array CGH showed reproducible results with high sensitivity and specificity in analyses of frozen tissue samples as well as in tissue samples that had been stored in RNAlater for at least 48 hours.
Surprisingly, these analyses did not identify a single breast cancer case with complete polysomy of chromosome 17, including two cases that were classified as polysomy 17 by FISH analysis. Polysomy of chromosome 17 in breast cancer has been widely reported and is presumed to be present when FISH analysis detects amplification of a chromosome 17 centromere probe. However, in our array CGH study that included 99 BAC clones for chromosome 17, we found that the term 'polysomy 17' is a misnomer and propose the alternate term 'centromere amplified' to describe cases with Z3 copies of the chromosome 17 centromere. Although polysomy of chromosome 17 was not observed in our study, complex rearrangements of chromosome 17 and amplification of genes other than HER2 were relatively common (detected in 52 (55%) cases). It is clear that array CGH can accurately assess true chromosome 17 status, and therefore, the lack of detection of such cases in our study suggests that gain of whole chromosome 17 is a rare event in breast cancer. However, polysomy of other chromosomes is not uncommon, as evidenced by finding 22 instances of complete chromosome gain in a total of 97 cases. Interestingly, only one breast cancer case showed multiple polysomy, with gains of chromosomes 4, 7, and 21. In the other 21 cases, no more than one whole chromosome gain was found per tumor genome.
Array CGH has many advantages over FISH for gene copy number determination, including the fact that it is a DNA-based test with the ability to both subjectively (by visualization of chromosome 17 ratio plots) and objectively (by calculation of fluorescence intensity ratios for HER2 probes) interpret HER2 status. Objective analysis can eliminate errors caused by reliance on interpretation of purely subjective results, as is the case with current HER2 testing. 27, 28 Although immunohistochemical staining for the HER2 protein will remain a necessary part of the breast cancer workup because of a small percentage of cases that show protein overexpression without gene amplification, we have shown that array CGH is a more reliable confirmatory method than FISH for determination of HER2 status, because it can provide whole-chromosome 17 analysis as well as a whole-genome view in a single test.
Optimal array CGH results require adequate highmolecular-weight DNA from fresh or frozen tumor tissue. Although array CGH can be carried out on formalin-fixed paraffin-embedded tissue (FFPE), significant differences are observed in the results obtained from FFPE tissue compared with fresh tissue owing to differences in fixation times and processing procedures at various institutions. We have developed two clinically validated breast cancer tissue procurement procedures for determination of HER2 status. These procedures consist of making an OCT block of fresh tissue or placing 25-50 mg of tissue into a tube of RNAlater, for subsequent sectioning, H and E staining, and tumortargeted DNA isolation. Array CGH is a DNA-based test; hence, if adequate tissue is available postoperatively for the assay (almost always the case at the time of lumpectomy or mastectomy, and less frequently for core biopsies and cytology specimens), then DNA from the original tumor can be obtained, analyzed by array CGH, and stored for current studies, as well as for future comparative studies, should the patient have a recurrence or metastatic event.
In conclusion, we have shown that array CGH can be used as a clinical tool for the determination of HER2 and chromosome 17 status in breast cancer samples. In addition, our analysis has clearly shown that polysomy 17 is a rare occurrence in breast cancer, as we were unable to show any cases of polysomy 17 in the evaluation of 97 breast cancer cases. This finding has important implications for currently used FISH methods to determine HER2 status, as it suggests that chromosome 17 copy number assessment methods that use a chromosome 17 centromere probe do not accurately assess chromosome 17 copy number. As array CGH becomes more widely available for clinical breast cancer testing in the future, patients will benefit from the improved prognosis, risk stratification, and treatment planning that results from an accurate assessment of not only of HER2 gene status but also the entirety of chromosome 17 and the rest of the tumor genome as well. a clinical consultant for CMDX. IY, ARB, and MAM declare no conflicts of interest.
